SANGAMO THERAPEUTICS INC (SGMO) Stock Price, Quote, News and Overview
NASDAQ:SGMO - Nasdaq - US8006771062 - Common Stock - Currency: USD
SGMO Quote, Performance and Key Statistics
SANGAMO THERAPEUTICS INC
NASDAQ:SGMO (2/5/2025, 12:50:07 PM)
1.27
+0.03 (+2.42%)
The current stock price of SGMO is 1.27 USD. In the past month the price decreased by -4.62%. In the past year, price increased by 115.88%.
SGMO Latest News, Press Releases and Analysis
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ: SGMO). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ: SGMO). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ: SGMO). Such...
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
SGMO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.97 | 339.25B | ||
| AMGN | AMGEN INC | 15.38 | 163.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 955.37 | 125.48B | ||
| GILD | GILEAD SCIENCES INC | 22.57 | 124.61B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.63 | 78.41B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.58B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.34B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.37B | ||
| NTRA | NATERA INC | N/A | 23.34B | ||
| BIIB | BIOGEN INC | 8.9 | 21.18B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.61 | 15.86B |
Related stock screener links
About SGMO
Company Profile
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Richmond California, California and currently employs 405 full-time employees. The company went IPO on 2000-04-06. The firm's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The firm's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Company Info
SANGAMO THERAPEUTICS INC
501 Canal Blvd.
Richmond California CALIFORNIA 94005 US
CEO: Alexander D. Macrae
Employees: 405
Company Website: https://www.sangamo.com/
Investor Relations: https://investor.sangamo.com
Phone: 15109706000
SGMO FAQ
What is the stock price of SGMO?
The current stock price of SGMO is 1.27 USD.
What is the symbol for SANGAMO THERAPEUTICS INC stock?
The exchange symbol of SANGAMO THERAPEUTICS INC is SGMO and it is listed on the Nasdaq exchange.
On which exchange is SGMO stock listed?
SGMO stock is listed on the Nasdaq exchange.
Is SGMO a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SGMO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SGMO.
Does SGMO stock pay dividends?
SGMO does not pay a dividend.
When does SGMO stock report earnings?
SGMO will report earnings on 2025-02-19, after the market close.
What is the Price/Earnings (PE) ratio of SGMO?
SGMO does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.75).
What is the Short Interest ratio of SGMO stock?
The outstanding short interest for SGMO is 11.07% of its float.
SGMO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to SGMO. When comparing the yearly performance of all stocks, SGMO is one of the better performing stocks in the market, outperforming 88.54% of all stocks.
SGMO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SGMO. SGMO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SGMO Financial Highlights
Over the last trailing twelve months SGMO reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS decreased by 48.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -165.31% | ||
| ROE | -470% | ||
| Debt/Equity | 0 |
SGMO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to SGMO. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 67.56% and a revenue growth -67.76% for SGMO